Want to see OCGN full AI Analyst Report?
Earnings Data
Report Date
Jul 31, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.05Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed substantial scientific and operational progress across multiple gene‑therapy programs (OCU400, OCU410, OCU410ST) including completed Phase 3 enrollment, strong early efficacy signals (46% lesion reduction, 50% responder rate, ~two-line LLVA gain, 60% slower EZ loss), a peer‑reviewed publication, a regional licensing deal, recent capital raise, and senior hires to support commercialization. Counterbalancing these positives are a limited cash runway into 2026 (dependence on uncertain warrant exercise and future financings), rising R&D spend (~24% year) and small/preliminary datasets that require confirmatory Phase 3 results. Overall, the highlights (clinical progress, regulatory alignment, partnerships, fundraising, leadership additions) meaningfully outweigh the risks, though execution and financing remain key near‑term priorities.Company Guidance
OCU400 Phase 3 Enrollment Complete
Limelight Phase 3 enrollment complete with 140 patients randomized 2:1 (treatment:control); gene-agnostic design covering major mutations (e.g., USH2A, XLRP, PDE6B). Top-line one‑year data expected in 2027, rolling BLA submission planned to begin in 2026 and potential commercialization targeted in 2027.
OCU400 Long-Term Phase 1/2 Data Demonstrate Durability and Safety
Positive three‑year Phase 1/2 data show sustained, clinically meaningful approximately two-line LLVA gain and durable, favorable safety/tolerability with no new treatment‑related serious adverse events reported.
OCU410 (GA) Early Efficacy Signals — ARMADA Phase 2
Preliminary 12‑month data (≈50% of patients evaluated; n cohort cited = 23) show a 46% reduction in lesion growth across combined medium/high doses versus control (p = 0.015). Observed 50% responder rate (>50% lesion size reduction vs control). Subgroup with baseline lesion ≥7.5 mm² showed 57% (medium) and 56% (high) reduction versus control. Phase 3 planned to initiate in 2026.
OCU410 Structural Benefit (EZ) and Phase 1 Findings
Phase 1 findings reported a 60% slower ellipsoid zone (EZ) loss rate in treated eyes versus untreated fellow eyes, indicating substantial slowing of photoreceptor degeneration; EZ included as key exploratory/structural endpoint across trials.
OCU410ST (Stargardt) Program Progress and Publication
Phase 2/3 Guardian‑3 pivotal trial remains ahead of schedule with top-line data anticipated in 2027. Peer‑reviewed Phase 1 Guardian results published in Nature Eye supporting favorable safety, tolerability, and efficacy. Interim EZ structural analysis showed approximately 16% lesion reduction at 12 months and 50% of treated eyes achieved EZ preservation exceeding expected decline.
Regulatory and Strategic Efficiency — EMA Alignment
CHMP/EMA confirmed U.S.-based trial data can support EMA application for OCU410ST, enabling timeline and budget efficiencies across U.S. and Europe development plans.
Business Development and Partnerships
Executed first regional licensing agreement for OCU400 (exclusive Korea rights with upfront, milestone payments and royalties), enabling near‑term value capture while preserving U.S./European rights. Strategy aims to maximize global patient reach while retaining core geographies.
Capital and Balance Sheet Actions
Raised $22.5M via an underwritten registered direct offering led by RTW Investments. Company notes current cash and cash equivalents extend runway into 2026; potential exercise of $30.0M in existing warrants could extend runway into 2027.
Organizational Strengthening
Key senior hires to support commercialization and operations: Abhi Gupta (EVP, Commercial & BD), Rita Johnson Green named CFO, and Paul Halsted (EVP, Operations) with significant biologics and gene therapy manufacturing experience.
Pipeline Breadth and Regulatory Designations
Portfolio progress includes OCU200 with no reported SAEs (enrollment expected complete in 2026), OCU500 enhanced vaccine Phase 1 intended to be initiated by NIAID in 2026, and Rare Pediatric Disease designation for OCU410ST; company created Arthroselix subsidiary to unlock regenerative assets value.
OCGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
OCGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $1.85 | $1.49 | -19.46% |
Mar 04, 2026 | $1.86 | $1.96 | +5.38% |
Nov 05, 2025 | $1.43 | $1.41 | -1.40% |
Aug 01, 2025 | $1.03 | $0.99 | -3.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ocugen Inc (OCGN) report earnings?
Ocugen Inc (OCGN) is schdueled to report earning on Jul 31, 2026, Before Open (Confirmed).
What is Ocugen Inc (OCGN) earnings time?
Ocugen Inc (OCGN) earnings time is at Jul 31, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OCGN EPS forecast?
OCGN EPS forecast for the fiscal quarter 2026 (Q2) is -0.05.
